이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Can-Fite BioPharma 관리

관리 기준 확인 4/4

Can-Fite BioPharma's CEO는 Motti Farbstein, Aug2003 에 임명되었습니다 의 임기는 21.08 년입니다. 총 연간 보상은 $ 467.00K, 66.4% 로 구성됩니다. 66.4% 급여 및 33.6% 보너스(회사 주식 및 옵션 포함). 는 ₪ 32.92 가치에 해당하는 회사 주식의 0% 직접 소유합니다. 32.92. 경영진과 이사회의 평균 재임 기간은 각각 21.1 년과 16.1 년입니다.

주요 정보

Motti Farbstein

최고 경영자

US$467.0k

총 보상

CEO 급여 비율	66.4%
CEO 임기	21.1yrs
CEO 소유권	0.00006%
경영진 평균 재임 기간	21.1yrs
이사회 평균 재임 기간	16.1yrs

최근 관리 업데이트

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

CEO 보상 분석

Motti Farbstein 의 보수는 Can-Fite BioPharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$467k	US$310k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$471k	US$298k	-US$10m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$484k	US$291k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$468k	US$313k	-US$15m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$277k	US$195k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$331k	US$186k	-US$7m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$315k	US$242k	-US$6m

보상 대 시장: Motti 의 총 보상 ($USD 467.00K )은 IL 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 437.99K ).

보상과 수익: Motti 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Motti Farbstein (60 yo)

21.1yrs

테뉴어

US$467,000

보상

Mr. Motti Farbstein serves as a Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Executive Officer since June 30, 2023. Mr. Farbstein served as Chief...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pnina Fishman	Founder	19yrs	US$703.00k	0.013% $ 7.1k
Motti Farbstein	CEO and Chief Financial & Operating Officer	21.1yrs	US$467.00k	0.000060% $ 31.9
Sari Fishman	Vice President of Business Development	10.7yrs	US$373.00k	데이터 없음
Ilan Cohn	Co-Founder & Director	30yrs	데이터 없음	0.0068% $ 3.6k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	1.1yrs	데이터 없음	데이터 없음

21.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: CANF 의 관리팀은 노련하고 경험 (평균 재직 기간 20.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pnina Fishman	Founder	19yrs	US$703.00k	0.013% $ 7.1k
Ilan Cohn	Co-Founder & Director	30.7yrs	데이터 없음	0.0068% $ 3.6k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	no data	데이터 없음	데이터 없음
Nabil Hanna	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yaacov Goldman	External Independent Director	7.1yrs	US$60.00k	데이터 없음
Abraham Sartani	Independent Director	23.7yrs	데이터 없음	데이터 없음
Guy Regev	Independent External Director	13.2yrs	US$60.00k	0.0012% $ 653.7
Scott L. Friedman	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Arun Sanyal	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Yoseph Bornstein	Independent External Director	3.1yrs	데이터 없음	데이터 없음
Rifaat Safadi	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Kim Papp	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음

16.1yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: CANF 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 15.8 년).

Can-Fite BioPharma 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Insufficient new directors

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Insufficient new directors

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Recent updates

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?